U.S., March 18 -- ClinicalTrials.gov registry received information related to the study (NCT07478302) titled 'A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma' on March 12.
Brief Summary: This study was a multicenter, open-label phase I clinical trial. This trial will include 36 patients with advanced unresectable hepatocellular carcinoma. Blood samples were obtained during the course of treatment to measure the relative parameter. All Investigational Medicinal Products (IMP) were discontinued after the total cycle.
Study Start Date: March, 2026
Study Type: INTERVENTIONAL
Condition:
Advanced Unresectable Hepatocellular Carcinoma
Intervention:
DRUG: SHR-2524 Injection
SHR-2524 inje...